422 related articles for article (PubMed ID: 19450663)
1. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Etievant A; Bétry C; Arnt J; Haddjeri N
Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
[TBL] [Abstract][Full Text] [Related]
2. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
[TBL] [Abstract][Full Text] [Related]
3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
4. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
[TBL] [Abstract][Full Text] [Related]
5. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
Novi F; Millan MJ; Corsini GU; Maggio R
J Neurochem; 2007 Aug; 102(4):1410-24. PubMed ID: 17532788
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity.
Bétry C; Etiévant A; Lambás-Señas L; McCreary AC; Haddjeri N
Synapse; 2011 Oct; 65(10):1042-51. PubMed ID: 21446003
[TBL] [Abstract][Full Text] [Related]
7. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
Millan MJ; Iob L; Péglion JL; Dekeyne A
Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.
Seeman P
Synapse; 2008 Dec; 62(12):902-8. PubMed ID: 18792990
[TBL] [Abstract][Full Text] [Related]
9. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
[TBL] [Abstract][Full Text] [Related]
10. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study.
Di Giovanni G; Di Matteo V; Di Mascio M; Esposito E
Synapse; 2000 Jan; 35(1):53-61. PubMed ID: 10579808
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of serotonin2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration.
Pierucci M; Di Matteo V; Esposito E
J Pharmacol Exp Ther; 2004 Apr; 309(1):109-18. PubMed ID: 14722316
[TBL] [Abstract][Full Text] [Related]
12. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
Tadori Y; Kitagawa H; Forbes RA; McQuade RD; Stark A; Kikuchi T
Eur J Pharmacol; 2007 Nov; 574(2-3):103-11. PubMed ID: 17692841
[TBL] [Abstract][Full Text] [Related]
13. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons.
Di Giovanni G; Di Mascio M; Di Matteo V; Esposito E
J Pharmacol Exp Ther; 1998 Oct; 287(1):51-7. PubMed ID: 9765321
[TBL] [Abstract][Full Text] [Related]
14. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
15. Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.
Di Clemente A; Franchi C; Orrù A; Arnt J; Cervo L
Addict Biol; 2012 Mar; 17(2):274-86. PubMed ID: 21521422
[TBL] [Abstract][Full Text] [Related]
16. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
17. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kikuchi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
[TBL] [Abstract][Full Text] [Related]
19. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.
Lejeune F; Millan MJ
Synapse; 1998 Oct; 30(2):172-80. PubMed ID: 9723787
[TBL] [Abstract][Full Text] [Related]
20. Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study.
Blackburn TP; Minabe Y; Middlemiss DN; Shirayama Y; Hashimoto K; Ashby CR
Synapse; 2002 Dec; 46(3):129-39. PubMed ID: 12325040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
